ATLANTA, GA – December 11, 2017 – Amniox Medical, Inc., a TissueTech, Inc. company, has been awarded a group purchasing agreement for Regenerative Skin Grafting Products with Premier. Effective January 1, 2018, the new agreement allows Premier members, at their discretion, to take advantage of special terms pre-negotiated by Premier for the full Amniox Medical portfolio, of wound and surgical solutions, which are known under the respective NEOX® and CLARIX® brand names.
“We’re pleased to partner with an organization that shares our vision of empowering physicians and their health systems to improve patient outcomes while reducing costs,” said Amniox Medical CEO Tom Dugan. “Premier’s membership represents leading medical centers and institutions across the U.S. This alliance with that network reflects our expanding presence delivering value in regenerative and restorative medicine.”
Amniox Medical is the first provider of a human tissue allograft composed of umbilical cord and amniotic membrane. The biological components of the tissue have demonstrated regenerative properties that can provide healing benefits to patients with numerous medical conditions. Amniox Medical utilizes its proprietary CRYOTEKä process, a cryopreservation technology proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments.
Premier is a leading healthcare improvement company, uniting an alliance of approximately 3,900 U.S. hospitals and 150,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.
About Amniox Medical, Inc.
Founded in 2011 to serve the orthopedic and wound care markets, Amniox Medical is dedicated to developing and marketing regenerative therapies processed from umbilical cord and amniotic membrane utilizing its proprietary CRYOTEK technology. Amniox Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety of its products. For additional information, please visit http://www.amnioxmedical.com.
About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and Bio-Tissue, Inc., pioneered the development and clinical application of regenerative, amniotic tissue-based products. Amniox Medical develops and markets products for use in the musculoskeletal and wound care markets; Bio-Tissue develops and markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) have supported TissueTech’s research with more than 30 continuous years of research grants. Since the company’s inception, clinicians have performed more than 300,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform. The Company’s first product, AmnioGraft® , is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.